mnmhealthcare

Marketing Automation is the ultimate software to automate recurring marketing tasks. It has become one of the favored tools of marketers. The software guides customers through their entire marketing journey and ensures that the customer satisfaction rate is high and helps retain customers. Marketing automation software also guides marketers in creating marketing strategies so that they can target the right audience and convert it into customers. The software plays an important role in increasing business revenue and business efficiency.

Marketing Automation Software is built completely on technological tools and thus with current technological advancements, there is expected to be high demand for this software. A few of the expected technological advancements that can be seen in the near future are listed below.

Machine Learning and Artificial Intelligence

Machine Learning and Artificial Intelligence are being implemented in every other software. Machine learning will enable organizations to build enhanced marketing campaigns. ML and AI will collect user data through these campaigns and help in generating leads. This information will be used in building more personalized campaigns and targeting the right group of potential customers.

Personalization

Personalization is trending in marketing automation. Customers tend to read emails and SMS messages to a higher extent if the content is personalized. This type of content enables organizations to concentrate on specific customer behavior and create content based on that. This behavior is collected by using ML & AI. The personalized content is delivered to potential customers at the right time so that it can be converted into sales.

Usage of Chatbots

Chatbots is one of the trending features that every other organization is implementing. They play a crucial role in building customer relationships. Chatbots interact with customers automatically and save time for marketers. These are very helpful as they answer a few basic questions that customers tend to ask.

Automated Social Media Marketing

There are many people joining social media on a daily basis. Therefore, social media is a superior platform to market products. As there are a significant number of people on social media, there are high chances of getting multiple leads by just posting content about various products offered by organizations. With automation, it becomes possible to create automatic posts for future dates and times. Thus, automation saves time for organizations in repetitively scheduling such posts and events.

Mobile Marketing

Mobile marketing is trending in the market with the increasing usage of smartphones or mobiles. Reaching out to potential customers becomes manageable through mobiles as these are used to a high extent. Vital information such as location, browsing style, and types of devices, various interests, and many more can be achieved using mobile automation. With this data, businesses can send personalized marketing emails or SMS messages that engage the right audience and help in creating the right strategies to convert such leads.

It will be helpful in making the best use of marketing automation in future and deciding whether to invest in it for these popular trends. Marketing automation is expected to definitely see more technological advancements that offer the best results for organizations.

Suggested Read: Best Marketing Automation Software Vendors 2020 and Benefits

About 360Quadrants

360Quadrants is the largest marketplace looking to disrupt USD 3.7 trillion of technology spend and is the only rating platform for vendors in the technology space. The platform provides users access to unbiased information that helps them make qualified business decisions. The platform facilitates deeper insights using direct engagement with 650+ industry experts and analysts and allows buyers to discuss their requirements with 7,500 vendors. Companies get to win ideal new customers, customize their quadrants, decide key parameters, and position themselves strategically in niche spaces, to be consumed by giants and start-ups alike. Experts get to grow their brand and increase their thought leadership. The platform targets the building of a social network that links industry experts with companies worldwide. The platform has approximately 400 buyers across various markets.

360Quadrants will also be launching quadrants in fields such as Email Marketing, Social Media Analytics Software, and Social Media Management Software.

Contact: Mr. Agney Sugla agney@marketsandmarkets.com 630 Dundee Road, Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Emerging countries such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities to market players in the coming years. The high growth in these markets can majorly be attributed to the improving healthcare infrastructure, increasing public healthcare expenditure, the presence of a large target patient population, and growing awareness and availability of advanced technologies.

Market Dynamics

1. High Risk of Chromosomal Abnormalities With Increasing Maternal Age
2. Growing Preference for Noninvasive Techniques Over Invasive Methods
3. Improving Reimbursement Scenario for NIPT
4. Programs Focusing on Increasing the Awareness of NIPT

Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market. This segment is also estimated to grow at the highest CAGR during the forecast period.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. RoW

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region

Some key players mentioned in the research report are:

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Get Sample Report @https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.

The global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025).

On the other hand, a lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, unstable payment models, and resistance from traditional healthcare providers are challenging the growth of this market to a certain extent.

Market Dynamics

1. Increasing incidence of preventable chronic diseases
2. Rising focus on preventive healthcare
3. Need to control healthcare costs
4. Significant increase in venture capital investments

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). In 2019, the B2B segment accounted for the largest market share; it is also expected to grow at the highest CAGR of the digital therapeutics market. There is growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics and the healthcare cost reductions achieved by their use.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market and register the highest CAGR during the forecast period. The high growth of this segment is attributed to company initiatives for the development of products specifically for caregivers and the fact that digital therapeutics help caregivers in better managing their patients.

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. RoW

The global digital therapeutics market is segmented into North America, Europe, the Asia Pacific, and the RoW. In 2019, North America (US and Canada) held the largest share of the market, followed by Europe. The major factors supporting market growth include the increasing investments in digital therapeutics, the influx of new start-ups, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements.

Some key players mentioned in the research report are:

The digital therapeutics market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).

Get Sample Report @https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.

What the Genotyping Assay Market Looks Like?

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period. North America is the largest regional market for glycomics

On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period. The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

What Drives the Genotyping Assay Market?

The growth of the global market Genotyping Assay Market is primarily influenced by the following factors:

• Technological Advancements and Decreasing Prices of DNA Sequencing
• Increasing Incidence of Genetic Diseases and Rising Awareness on Personalized Medicine
• Growing Importance of Genotyping in Drug Development
• Increasing Demand for Bioinformatics Solutions in Data Analysis
  
  

The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

Recent Developments

• In June 2019, Agilent Technologies (US) has launched InfinityLab LC/MSD iQ System
• In June 2018, Thermo Fisher Scientific (US) had launched UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer.
  
  

Geographical growth scenario of Genotyping Assay Market:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

Leading market players and strategies adopted

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five. Illumina also provides reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and other sequencing reagents, along with sequencing services such as whole-genome sequencing, human whole-exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and other related services.

Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

The growth of the market can be attributed to increasing drug discovery activities, the growing biopharmaceutical industry, and the rising trend in outsourcing compound/sample management. The rising drug discovery activity is leading to an increased demand for compounds, which is positively affecting market growth.

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

In 2013, the FDA approved the first and only product for alpha emitters in the market, launched by Bayer AG under the name Xofigo (a Ra-223 dichloride molecule). The North American market for Ra-223 is expected to command the largest share owing to its targeted properties over beta emitters and being the only alpha-emitter product available in the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108

Global North American Nuclear Medicine/Radiopharmaceuticals Market is Segmented on:

1. Type
2. Therapeutic
3. Application

Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

The rising drug discovery activity, coupled with increasing pharmaceutical companies, is the major factor driving the growth of the segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108

The geographical regions mapped in the report are:

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Some key players mentioned in the research report are:

Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

• The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from   USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.
  
  

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.

The trisomy applications segment accounted for the largest share of the global NIPT market in 2018.

Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market.

Get a PDF Copy of the Sample Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.

Non-invasive Prenatal Testing Products Market, by Method

• Ultrasound Detection
• Biochemical Screening Tests
• Cell-free DNA in Maternal Plasma Tests
  
  

Non-invasive Prenatal Testing Market, by Application

• Trisomy
• Microdeletion Syndrome
• Other Applications
  
  

Non-invasive Prenatal Testing Products Market, by End User

• Diagnostic Laboratories
• Hospitals
  
  

The geographical regions mapped in the report are:

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Rest of Europe (RoE)
• Asia
• Rest of the World (RoW)
  
  

For getting 10% customization Please click here @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=145607690

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region

Some key players mentioned in the research report are:

• The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK) 
• Illumina is one of the major players in the non-invasive prenatal testing market. The company offers a range of highly interconnected products related to sequencing, genotyping, gene expression, and molecular diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and support services which further strengthen its market position.

Read more about NIPT market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost. On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period.

What the Pharmacy Automation Market Looks Like?

MarketsandMarkets forecasts the pharmacy automation market is estimated to grow from USD 3.63 billion in 2017 to USD 5.38 Billion by 2022, at a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period. North America to account for the largest market size during the forecast period.

Based on product, the pharmacy automation market is segmented into automated medication dispensing systems, automated packaging and labelling systems, automated table top counters, automated medication compounding systems, automated storage and retrieval systems, and other pharmacy automation systems. Automated medication dispensing systems accounted for the largest share of the pharmacy automation market in 2016.

On the basis of end users the market is classified into inpatient pharmacies, outpatient pharmacies, pharmacy benefit management organization and mail order pharmacies, and retail pharmacies. Retail pharmacies is the fastest growing end user segment in the pharmacy automation market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890

What Drives the Pharmacy Automation Market?

The growth of the global market for Pharmacy Automation Market is primarily influenced by the following factors:

• Growing Need to Minimize Medication Errors
• Decentralization of Pharmacies
• Rising Geriatric Population
• Rising Labor Cost

Recent Developments :

• In 2017, Omnicell launched Omnicell VBM 200F. It fills and checks SureMed multiple medication blister cards
• In 2017, Omnicell partnered with DCH Health Systems to implement a full suite of IV compounding technology across its health system
• In 2017, BD opened its new institute for medication management excellence. This institute is designed to identify and support advancements in medication management to help improve the safety and cost of healthcare
• In 2016, Omnicell acquired Ateb, Inc., which provides pharmacy-based patient care solutions and medication synchronization to independent and chain pharmacies
• In 2015, BD acquired CareFusion Corporation, a global medical technology company with a comprehensive portfolio of products in the areas of medication management, infection prevention, operating room & procedural effectiveness, and respiratory care

For getting 10% customization Please click here @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=71522890

Geographical growth scenario of Pharmacy Automation Market :

This report covers the market across two major geographies, namely, North America and Europe. In this report, the North American market is further segmented into the U.S. and Canada, while the European market is categorized into Germany, U.K., France, Italy, Spain, and Rest of Europe. In 2016, North America is expected to command the largest share of the market in North America and Europe. However, Europe is expected to register the highest growth rate during the forecast period from 2016 to 2021, due to increasing adoption of advanced treatment procedures and favorable government initiatives in this region.

Leading market players and strategies adopted

The prominent players in the Pharmacy Automation Market include 
Becton, Dickinson, and Company (U.S.), Omnicell, Inc. (U.S.), Cerner Corporation (U.S.), Capsa Healthcare (U.S.), Parata Systems LLC (U.S), Baxter International, Inc. (U.S.), ScriptPro LLC (U.S.), KUKA AG (Germany), TCGRx Pharmacy Workflow Solutions (U.S.), RxSafe, LLC (U.S.), ARxIUM Inc. (U.S.) and Talyst Systems, LLC (U.S.)

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71522890

Growth of the market is mainly driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management.

The global radiation dose management market size is projected to reach USD 423 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% during the forecast period.

Based on product & service, the radiation dose management market is segmented into radiation dose management solutions and radiation dose management services. The radiation dose management solutions segment is projected to witness the highest growth during the forecast period. The increasing adoption of radiation dose management solutions by healthcare providers owing to the growing regulations regarding ionizing radiation across the globe is the major factor supporting the growth of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82326344

Global Non Invasive Prenatal Testing (NIPT) Market is Segmented on:

1. Product
2. Services, Method
3. Application
4. End User

By modality, the radiation dose management market is segmented into computed tomography (CT), fluoroscopy & interventional imaging, mammography, and nuclear medicine. The computed tomography segment accounted for the largest market share in 2019. The large share of this segment can be attributed to the increasing number of CT examinations worldwide and the rising awareness of radiation dose exposure.

Based on end-users, the radiation dose management market is segmented into hospitals, ambulatory care settings, and other end users.

The hospital segment accounted for the largest share of the radiation dose management market in 2019. The rising patient population, growing awareness about the benefits of early disease diagnosis, technological advancements in imaging modalities, and the increasing awareness of the harmful effects of radiation exposure are some of the major factors responsible for the high demand for radiation dose management solutions in hospitals.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=82326344

The geographical regions mapped in the report are:

Based on the region, the radiation dose management market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the radiation dose management market. The large share of North America can be attributed to factors such as the stringent legislative and accreditation requirements regarding the reporting and optimization of radiation doses, high adoption of HCIT technologies, and the presence of stringent regulatory requirements regarding patient safety.

Some key players mentioned in the research report are:

Some of the major players operating in this market are Bayer AG (Germany), GE Healthcare (US), Philips Healthcare (Netherland), and Sectra AB (Sweden). In 2019, Bayer AG held the leading position in the radiation dose management market. The company has an extensive geographical presence spanning North America, Europe, Asia Pacific, and Latin America.

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on the prevention of diseases.

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%.

What Drives the Market?

1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government Bodies
5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants

The research applications segment is expected to account for the largest share of the market during the forecast period. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is expected to have a higher growth rate in the application category segment.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016.

Target Audience for this Report:

# Vaccine adjuvants manufacturers and suppliers
# Academic research institutes
# Biopharmaceutical and biotechnology companies
# Research and development (R&D) companies
# Business research and consulting service providers
# Medical research laboratories
# Academic medical centers and universities

On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.

For getting 10% customization Please click here @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

The vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries

Some key players mentioned in the research report are:

Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

• The global bioinformatics market is expected to account for USD 7,063.7 billion in 2018. It is expected to reach USD 13,901.5 billion by 2023, at a CAGR of 14.5% during the forecast period.

• Asia-Pacific (Japan, China, India, RoAPAC)
• North America (US and Canada)
• Europe (Germany, France, UK and RoE)
• Rest of World

• The Ambulatory surgical centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period.

Recent Developments :

• In 2019, NextGen Healthcare launched NextGen Health Data Hub
• In 2019, GE Healthcare launched Edison Datalogue and my. Cryochain software
• In 2019, MEDITECH collaborated with Google to offer EHR data through the Google Cloud Platform. This helped to securely deliver patient data, enhance scalability, and facilitate interoperability.
• In 2019, Epic Systems partnered with Teledoc Health to integrate Teledoc Health’s virtual care platform to Epic’s App Orchard that would help the company conduct telehealth video visits.

To get a 10% Customization on the report, click@ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=182183086

Factors such as rising prevalence of chronic and acute diseases increase in the aging population, new product launches, and technological advancements are driving the growth of this market. On the other hand, high cost of technological advancements, lack of trained professionals, accuracy of the devices and short shelf life is hindering the growth of this market.

The overall market for pressure monitoring is expected to reach $8,040.6 million by 2020 from $6,000.0 million in 2015, growing at a CAGR of 5.0% from 2015 to 2020.

Pressure Monitoring Market Size & Share by Product (Device (Blood Pressure, Intracranial Pressure, Intraocular Pressure), Accessory), Application (Respiratory, Glaucoma, Dialysis), Procedure (Invasive), End User (Hospital, ASC, Diagnostic) – Global Forecast to 2020

Request for Sample Report : https://www.marketsandmarkets.com/requestsampleNew.asp?id=196787732

Pressure monitoring plays an important role in detecting the health problems of a patient. The major fluctuations of pressure in the vital areas of the body may cause various chronic and acute diseases such as diabetes, cardiac arrest, and glaucoma.

Pressure monitoring plays an important role in detecting the health problems of a patient. The major fluctuations of pressure in the vital areas of the body may cause various chronic and acute diseases such as diabetes, cardiac arrest, and glaucoma. Increase in the prevalence of the above mentioned diseases and growing aging population have increased the need for pressure monitoring and control in the market.

Increase in the prevalence of the above mentioned diseases and growing aging population have increased the need for pressure monitoring and control in the market.
The major factors responsible for the growth of the pressure monitoring are the rising prevalence of chronic and acute diseases, growth of aging population, new product launches, increase in the lifestyle related diseases, and technological advancements.

Due to these factors, the demand for pressure monitoring is increasing. On the other hand, lack of trained professionals, short shelf life of the device, accuracy of devices has may restrain the growth of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=196787732

The geographical regions mapped in the report are:

1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East and Africa

Geographical Growth Analysis:

Geographically, the market is dominated by North America, followed by Europe. North America is expected to account for the largest share of the global market in 2015, with Asia having the highest growth rate during the forecast period.

North America dominates the market, accounting for a major market share in 2014. Factors such as increasing prevalence of chronic and acute diseases such as hypertension and cardiac diseases, technological advancements, acceptability of the non-invasive pressure monitors among the patients, and existence of key market players in North America are driving the growth of this market.

Some key players mentioned in the research report are:

Key players in the Pressure Monitoring Market include Philips Healthcare (The Netherlands), GE Healthcare (U.K.), Welch Allyn, Inc. (U.S.), Medtronic (U.S.), and Drägerwerk AG & Co. KGaA (Germany).

Biologics are pharmaceutical products that are extracted from biological sources. Biologics safety testing is carried out by manufacturers to detect contaminants like bacterial toxins, mycoplasma, and viruses. It is a mandatory process in these companies for the quality control of raw materials as well as for process control and validation of end products.

•  The global biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period.

What Drives the Market?

1. Growth in Pharmaceutical and Biotechnology Industries Driven By Government Support
2. Positive Trend of R&D Investments in Life Science
3. Increase in Number of Drug Launches
4. High Incidence and Large Economic Burden of Chronic Diseases

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases. In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the biologics safety testing market.

The kits & reagents segment is projected to register the highest during the forecast period. The growth of this market segment is driven by repeat purchase of kits and reagents as compared to instruments and increasing adoption of kit-based testing.

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

North America is expected to account for the largest share of this market. The strong R&D trend in life sciences and growth in pharmaceutical industries will drive the biologics safety testing market in the North American region.

Some key players mentioned in the research report are:

Lonza Group LTD, Charles River Laboratories, Merck KGaA, SGS SA, WuXi Apptec, Thermo Fisher Scientific Inc, Sartorius AG, Cytovance Biologics, Inc, Pace Analytical Services Inc, and Toxikon Corporation.

Get Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144

Growth of the market is mainly driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management.

The global radiation dose management market size is projected to reach USD 423 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% during the forecast period.

Based on product & service, the radiation dose management market is segmented into radiation dose management solutions and radiation dose management services. The radiation dose management solutions segment is projected to witness the highest growth during the forecast period. The increasing adoption of radiation dose management solutions by healthcare providers owing to the growing regulations regarding ionizing radiation across the globe is the major factor supporting the growth of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82326344

Global radiation dose management market is Segmented on:

1. Products & Services
2. Modality
3. Application
4. End User

Based on the region, the radiation dose management market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the radiation dose management market. The large share of North America can be attributed to factors such as the stringent legislative and accreditation requirements regarding the reporting and optimization of radiation doses, high adoption of HCIT technologies, and the presence of stringent regulatory requirements regarding patient safety.

By modality, the radiation dose management market is segmented into computed tomography (CT), fluoroscopy & interventional imaging, mammography, and nuclear medicine. The computed tomography segment accounted for the largest market share in 2019. The large share of this segment can be attributed to the increasing number of CT examinations worldwide and the rising awareness of radiation dose exposure.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=82326344

The geographical regions mapped in the report are:

Based on the region, the radiation dose management market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the radiation dose management market. The large share of North America can be attributed to factors such as the stringent legislative and accreditation requirements regarding the reporting and optimization of radiation doses, high adoption of HCIT technologies, and the presence of stringent regulatory requirements regarding patient safety.

Some key players mentioned in the research report are:

Some of the major players operating in this market are Bayer AG (Germany), GE Healthcare (US), Philips Healthcare (Netherland), and Sectra AB (Sweden). In 2019, Bayer AG held the leading position in the radiation dose management market. The company has an extensive geographical presence spanning North America, Europe, Asia Pacific, and Latin America.

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases.

•  The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category – Forecasts to 2021

Browse 90 market data tables with 42 figures spread through 156 pages
Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

Vaccine Adjuvants market is segmented based on product type, route of administration, disease type, applications, and application category.

On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.

High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.

Based on route of administration, the vaccine adjuvants market includes oral route, subcutaneous route, intranasal route, intramuscular route, intradermal route, and other routes. The intramuscular segment is expected to account for the largest share of the global market in 2016. Rising geriatric population and vaccines for improved immunization are the key factors propelling the growth of this market.

Request Sample Report of vaccine adjuvants market : https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

Regional Growth, Development and Demand Analysis:

The global vaccine adjuvants market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India. Rising prevalence of infectious diseases, increasing government investments for vaccine research and development, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian region.

Key Players:

Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Customization Options:
1. Company Information: Detailed company profiles of five or more market players
2. Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

• The Ambulatory surgical centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period.

Recent Developments :

• In 2019, NextGen Healthcare launched NextGen Health Data Hub
• In 2019, GE Healthcare launched Edison Datalogue and my. Cryochain software
• In 2019, MEDITECH collaborated with Google to offer EHR data through the Google Cloud Platform. This helped to securely deliver patient data, enhance scalability, and facilitate interoperability.
• In 2019, Epic Systems partnered with Teledoc Health to integrate Teledoc Health’s virtual care platform to Epic’s App Orchard that would help the company conduct telehealth video visits.

To get a 10% Customization on the report, click@ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=182183086